Clinical outcomes of second‐line treatment following first‐line VEGFR‐TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti‐PD‐1 antibody-Reference-Cited by-同舟云学术

Clinical outcomes of second‐line treatment following first‐line VEGFR‐TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti‐PD‐1 antibody

Published:2021-08-07 Issue:10 Volume:41 Page:1071-1074
ISSN:2523-3548
Container-title:Cancer Communications
language:en
Short-container-title:Cancer Communications

Author:

Huang Jiwei¹^ORCID,Wang Yueming¹,Zhang Haoran²,Hu Xiaoyi³,Wang Ping⁴,Cai Wen⁵,Yuan Yichu⁵,Zeng Hao²,Zhang Jin¹,Kong Wen¹,Huang Yiran¹,Wang Shuo⁴,Guo Jianming³,Wei Qiang²,Xue Wei¹

Affiliation:

1. Department of Urology, Renji Hospital School of Medicine, Shanghai Jiao Tong University Shanghai 200127 P. R. China

2. Department of Urology West China Hospital, Sichuan University Chengdu Sichuan 610041 P. R. China

3. Department of Urology Zhongshan Hospital, Fudan University Shanghai 200032 P. R. China

4. Department of Urology First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang 310003 P. R. China

5. Department of Urology Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang 310009 P. R. China

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cac2.12206

Reference10 articles.

1. Systemic Therapy for Metastatic Renal-Cell Carcinoma

2. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

3. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor‐based Combination Therapies for Treatment‐naive Metastatic Clear‐cell Renal Cell Carcinoma Are Standard of Care [published online ahead of print, 2021 May 29];Bedke J;Eur Urol,2021

4. Pembrolizumab (pembro) plusaxitinib (axi) versus sunitinib as first‐line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE‐426 study;Brian R;J Clin Oncol.,2019

5. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New clinical trial design in precision medicine: discovery, development and direction;Signal Transduction and Targeted Therapy;2024-03-04

2. Construction and Validation of Protein Expression-related Prognostic Models in Clear Cell Renal Cell Carcinoma;Journal of Cancer;2023

3. Perirenal Fat Thickness Significantly Associated with Prognosis of Metastatic Renal Cell Cancer Patients Receiving Anti-VEGF Therapy;Nutrients;2022-08-18

4. The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy;Frontiers in Oncology;2021-12-09